7MW4811 is developed with Mabwell's next-generation ADC technology (IDDC™) platform, and has demonstrated encouraging anti-tumor effects across a range of solid tumors, including lung, colorectal, ...

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.

The EMA has accepted a MAA for Alvotech and Advanz Pharma’s AVT05, a proposed biosimilar to Johnson & Johnson’s (J&J) Simponi ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

Alvotech (ALVO) has released an update. Alvotech, in collaboration with Advanz Pharma, has announced the acceptance of its Marketing ...

Alvotech (ALVO) and Advanz Pharma announced that the European Medicines Agency has accepted a Marketing Authorization Application for AVT05, ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

The FDA’s anticipated decision and EMA’s expected opinion are anticipated in the second half of 2025. Baca Juga Teva Statement on European Commission Decision; Company to Appeal TVB-009P, Teva’s ...

A preview of the next edition of BioWorld, ...

Biogen BIIB reported third-quarter 2024 adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate ...

Organon (NYSE:OGN) and partner Shanghai Henlius Biotech said the FDA has accepted the Biologics License Application for HLX14 ...